IPCALAB Share Price Performance
₹0
-1444.40 (-100.00%)
Price ₹0
Fair Value₹1,719.61
Share Pricen/a
Narrative Update • Jul 03
Ipca Laboratories Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
IPCALAB Community Narratives
AN
Fair Value
·Fair Value ₹1.72k 4.0% overvalued intrinsic discount
Domestic Chronic Focus And API Capacity Will Foster Global Opportunities
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value ₹1.52k 17.8% overvalued intrinsic discount
Rising Regulations And Cost Pressures Will Limit Pharma Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹1.89k 5.3% undervalued intrinsic discount
Emerging Markets In Asia And Africa Will Fuel Healthcare Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Regulations And Cost Pressures Will Limit Pharma Prospects
Ipca Laboratories looks set to face tougher rules, price pressure, and supply chain shocks that could slow new product launches and squeeze profits—especially if it stays too dependent on a few products and markets. But the picture isn’t one-sided: strong growth at home, new factories coming online, and better results from a recent takeover could still improve earnings if execution holds up.Read more
AN
₹1.52k
17.8% overvalued intrinsic discount
Fair Value
Revenue
10.4% p.a.
Profit Margin
14.45%
Future PE
29.16x
Price in 2029
₹2.16k
Domestic Chronic Focus And API Capacity Will Foster Global Opportunities
Ipca Laboratories is betting on everyday medicines for long-term conditions and a bigger ingredient-making footprint to grow at home while opening more doors overseas. The upside hinges on smoother integration of its Unichem deal and faster product rollouts, but ongoing losses in some units and tough pricing abroad could hold results back.Read more
AN
₹1.72k
4.0% overvalued intrinsic discount
Fair Value
Revenue
11.3% p.a.
Profit Margin
14.64%
Future PE
31.83x
Price in 2029
₹2.45k
Emerging Markets In Asia And Africa Will Fuel Healthcare Demand
Ipca Laboratories could ride rising healthcare demand in fast-growing regions as it expands into long-term treatments, pushes deeper into big cities, and brings new manufacturing sites online. But weak exports, regulatory setbacks, and the risk that an acquisition takes longer to pay off could still hold back the story.Read more
AN
₹1.89k
5.3% undervalued intrinsic discount
Fair Value
Revenue
13.41% p.a.
Profit Margin
14.53%
Future PE
32.67x
Price in 2029
₹2.68k
Trending Discussion
Recently Updated Narratives
AN
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Fair Value: ₹1.52k 17.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Fair Value: ₹1.72k 4.0% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Fair Value: ₹1.89k 5.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ipca Laboratories Limited Key Details
About IPCALAB
- Founded
- 1949
- Employees
- 16778
- CEO
- WebsiteView website
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
